Vivesto AB (VIVE.ST)
SEK 0.27
(-1.45%)
SEK 0.27
(-1.45%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -367.03 Million SEK | -164.15% |
| 2021 | -138.94 Million SEK | -1219.14% |
| 2020 | -10.53 Million SEK | 0.0% |
| 2019 | -10.53 Million SEK | 93.84% |
| 2018 | -171.02 Million SEK | -44.92% |
| 2017 | -118 Million SEK | 26.36% |
| 2016 | -160.24 Million SEK | -13.21% |
| 2015 | -141.53 Million SEK | -20.46% |
| 2014 | -117.49 Million SEK | -11.78% |
| 2013 | -105.11 Million SEK | -45.22% |
| 2012 | -72.38 Million SEK | -10.22% |
| 2011 | -65.67 Million SEK | 0.44% |
| 2010 | -65.96 Million SEK | -286.77% |
| 2009 | -17.05 Million SEK | -140.03% |
| 2008 | -7.1 Million SEK | -40.22% |
| 2007 | -5.06 Million SEK | 48.07% |
| 2006 | -9.75 Million SEK | -33.53% |
| 2005 | -7.3 Million SEK | -391.65% |
| 2004 | 2.5 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q1 | -19.15 Million SEK | 91.19% |
| 2023 Q2 | -28.17 Million SEK | -47.05% |
| 2022 Q3 | -71.93 Million SEK | -78.25% |
| 2022 FY | -367.03 Million SEK | -164.15% |
| 2022 Q1 | -25.08 Million SEK | -780.62% |
| 2022 Q2 | -40.35 Million SEK | -60.85% |
| 2022 Q4 | -217.38 Million SEK | -202.21% |
| 2021 Q1 | -40.81 Million SEK | 81.3% |
| 2021 Q4 | -2.84 Million SEK | 90.81% |
| 2021 Q2 | -57.67 Million SEK | -41.32% |
| 2021 Q3 | -30.98 Million SEK | 46.27% |
| 2021 FY | -138.94 Million SEK | -1219.14% |
| 2020 Q1 | 107.06 Million SEK | 280.81% |
| 2020 Q2 | -53.1 Million SEK | -149.6% |
| 2020 Q3 | -53.53 Million SEK | -0.82% |
| 2020 Q4 | -218.23 Million SEK | -307.63% |
| 2020 FY | -10.53 Million SEK | 0.0% |
| 2019 Q1 | -48.67 Million SEK | -60.77% |
| 2019 Q4 | -59.21 Million SEK | -220.86% |
| 2019 FY | -10.53 Million SEK | 93.84% |
| 2019 Q3 | -18.45 Million SEK | 53.78% |
| 2019 Q2 | -39.92 Million SEK | 17.96% |
| 2018 Q2 | -31.09 Million SEK | 3.19% |
| 2018 FY | -171.02 Million SEK | -44.92% |
| 2018 Q4 | -30.27 Million SEK | 50.36% |
| 2018 Q1 | -32.11 Million SEK | -10.44% |
| 2018 Q3 | -60.98 Million SEK | -96.12% |
| 2017 Q2 | -31.71 Million SEK | 24.64% |
| 2017 Q4 | -29.08 Million SEK | -15.91% |
| 2017 FY | -118 Million SEK | 26.36% |
| 2017 Q3 | -25.09 Million SEK | 20.88% |
| 2017 Q1 | -42.08 Million SEK | -5.48% |
| 2016 FY | -160.24 Million SEK | -13.21% |
| 2016 Q1 | -32.98 Million SEK | -30.15% |
| 2016 Q4 | -39.89 Million SEK | 3.5% |
| 2016 Q3 | -41.34 Million SEK | -11.98% |
| 2016 Q2 | -36.92 Million SEK | -11.94% |
| 2015 Q1 | -30.08 Million SEK | -8.54% |
| 2015 Q4 | -25.34 Million SEK | 41.6% |
| 2015 Q2 | -39.81 Million SEK | -32.37% |
| 2015 Q3 | -43.39 Million SEK | -8.98% |
| 2015 FY | -141.53 Million SEK | -20.46% |
| 2014 Q2 | -32.98 Million SEK | 12.71% |
| 2014 Q3 | -26.71 Million SEK | 19.02% |
| 2014 Q4 | -27.71 Million SEK | -3.74% |
| 2014 Q1 | -37.79 Million SEK | -24.17% |
| 2014 FY | -117.49 Million SEK | -11.78% |
| 2013 Q4 | -30.43 Million SEK | -63.1% |
| 2013 Q3 | -18.66 Million SEK | -2.4% |
| 2013 Q2 | -18.22 Million SEK | 20.6% |
| 2013 Q1 | -22.95 Million SEK | -47.7% |
| 2013 FY | -105.11 Million SEK | -45.22% |
| 2012 Q3 | -14.56 Million SEK | 24.63% |
| 2012 Q4 | -15.54 Million SEK | -6.7% |
| 2012 FY | -72.38 Million SEK | -10.22% |
| 2012 Q1 | -19.73 Million SEK | -14.5% |
| 2012 Q2 | -19.32 Million SEK | 2.1% |
| 2011 Q4 | -17.23 Million SEK | -1057.69% |
| 2011 FY | -65.67 Million SEK | 0.44% |
| 2011 Q1 | -21.51 Million SEK | -37.66% |
| 2011 Q2 | -15.26 Million SEK | 29.07% |
| 2011 Q3 | -1.48 Million SEK | 90.24% |
| 2010 Q2 | -12.09 Million SEK | -124.43% |
| 2010 Q3 | -16.72 Million SEK | -38.37% |
| 2010 Q4 | -15.62 Million SEK | 6.58% |
| 2010 FY | -65.96 Million SEK | -286.77% |
| 2010 Q1 | -5.38 Million SEK | 53.91% |
| 2009 Q4 | -11.68 Million SEK | -24.81% |
| 2009 Q2 | 9.38 Million SEK | 0.0% |
| 2009 Q3 | -9.36 Million SEK | -199.78% |
| 2009 FY | -17.05 Million SEK | -140.03% |
| 2008 FY | -7.1 Million SEK | -40.22% |
| 2007 FY | -5.06 Million SEK | 48.07% |
| 2006 FY | -9.75 Million SEK | -33.53% |
| 2005 FY | -7.3 Million SEK | -391.65% |
| 2004 FY | 2.5 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | -2580.812% |
| AlzeCure Pharma AB (publ) | -37.16 Million SEK | -887.516% |
| BioGaia AB (publ) | 365.35 Million SEK | 200.459% |
| Enzymatica AB (publ) | -49.72 Million SEK | -638.075% |
| Enorama Pharma AB (publ) | -44.61 Million SEK | -722.697% |
| Gabather AB (publ) | -9.43 Million SEK | -3789.266% |
| Klaria Pharma Holding AB (publ.) | -35.78 Million SEK | -925.682% |
| Moberg Pharma AB (publ) | -21.09 Million SEK | -1640.056% |
| Nanexa AB (publ) | -76.39 Million SEK | -380.418% |
| Newbury Pharmaceuticals AB (publ) | -15.4 Million SEK | -2282.538% |
| ODI Pharma AB | 355.97 Thousand SEK | 103206.714% |
| Orexo AB (publ) | -128.3 Million SEK | -186.072% |
| Probi AB (publ) | 16.81 Million SEK | 2282.234% |
| Swedencare AB (publ) | 58.6 Million SEK | 726.331% |
| Swedish Orphan Biovitrum AB (publ) | 2.4 Billion SEK | 115.236% |
| Toleranzia AB | -7.45 Million SEK | -4820.633% |